Haemonetics (HAE) PT Raised to $40 at Jefferies
Get Alerts HAE Hot Sheet
Rating Summary:
6 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 8 | New: 1
Join SI Premium – FREE
Jefferies analyst Anthony Petrone reiterated a Buy rating and raised his price target on Haemonetics (NYSE: HAE) to $40.00 (from $32.00) following mixed Q1 with $3mn top-line beat offset by a $0.03 EPS miss,
commented, "Underlying growth trends in Plasma and TEG were as expected and guidance was reiterated. The company announced a three-phase turnaround plan that aims to double adjusted OI and increase FCF by 4.0x over the next five years. We model 5-year estimates toward these aspirational goals and set a PT of $40 as the long awaited revamping gets underway."
The firm raised Q2 EPS from $0.32 to $0.33, FY 2017 EPS from $1.36 to $1.45 and FY 2018 EPS from $1.49 to $1.77.
For an analyst ratings summary and ratings history on Haemonetics click here. For more ratings news on Haemonetics click here.
Shares of Haemonetics closed at $33.52 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Upgrades Husqvarna AB (HUSQB:SS) to Buy
- Central Asia Metals Plc. (CAML:LN) PT Raised to GBP2.15 at Canaccord Genuity
- Stifel Downgrades Caterpillar (CAT) to Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!